CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS

Product Development Milestones

Updates regarding the development of biological and AI products funded by CPRIT, including clinical trial status.

For Fiscal Year 2022

1. Hummingbird Bioscience Inc. announced on September 13, 2021, the approval from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials for HMBD-002, the company's anti-VISTA neutralizing antibody. The company developed HMBD-002 for the treatment of cancers with VISTA-mediated immune suppression, including triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). The Phase 1, multi-center, open-label trial will evaluate HMBD-002, as a monotherapy and in combination with pembrolizumab. Researchers will assess safety and tolerability in a dose escalation study in patients with advanced solid malignancies. Hummingbird Bioscience, Inc. received a $13.1 million CPRIT Product Development Research grant (DP190027) in 2019.

2. OncoNano Medicine, a clinical-stage company that uses molecular cooperativity in drug design to diagnose and treat cancer, announced it is expanding its collaboration with The University of Texas Southwestern Medical Center on September 21, 2021. The multi-year collaboration will focus on discovering and conducting research of novel cancer therapeutics that leverage OncoNano's nanotechnology platform—which can "light up" cancer for real-time surgical imaging. OncoNano will sponsor research efforts in the laboratory of UT Southwestern's Jinming Gao, Ph.D., professor, Department of Cell Biology, Elaine Dewey Sammons Distinguished Chair in Cancer Research, with the goal of uncovering new cancer therapies that can benefit from OncoNano's ultra pH-sensitive polymeric micelles. In return, OncoNano will have an exclusive option to license new technology arising from the research conducted under this agreement. OncoNano Medicine, Inc. has received three CPRIT Product Development Research grants (DP140072, DP190066, DP200081) in 2014, 2019 and 2020, respectively, for a total of $31.4 million.

3. Houston-based biopharmaceutical company Salarius Pharmaceuticals, Inc. announced on September 22, 2021, that it has formed a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to study potential biomarkers for Salarius' lead drug candidate, seclidemstat. Seclidemstat (SP-2577) is a novel, oral, reversible inhibitor of lysine-specific histone demethylase 1, also referred to as LSD1, an enzyme that plays a key role in the development and progression of several cancers. A Phase 1/2 clinical trial is now underway exploring seclidemstat as a therapy for sarcomas. This trial is treating patients with myxoid liposarcoma and other FET-rearranged sarcomas with single-agent seclidemstat and evaluating seclidemstat in combination with the chemotherapy agents topotecan and cyclophosphamide as a potential second- and third-line therapy for Ewing sarcoma, a deadly pediatric bone cancer. Salarius Pharmaceuticals received a $16 million CPRIT Product Development Research grant (DP160014) in 2016.

4. The Texas Medical Center in Houston is, in terms of sheer size, the largest medical research center in the world, but it lags other hubs when it comes to launching billion-dollar startups. A new development called TMC3 broke ground in September 2021. The master plan calls for a radically transformed urban space where innovation, life-saving science and potentially billion-dollar developments all coexist. The plan includes 5 million square feet of buildings with restaurants and shops on the first floors, organized around a series of parks resembling the double helix of a DNA molecule. TMC3 could help open a new chapter in the center's success, however, helping the whole region. It represents a pivot that could bring institutions together to form a greater whole in way that attracts investment capital, jobs and talent.

5. Iterion Therapeutics, Inc. announced the initiation of a Phase 1 clinical trial to investigate tegavivint as a potential treatment for acute myeloid leukemia (AML) in October 2021. In AML preclinical models, tegavivint has shown single agent and combination efficacy with chemotherapy and targeted agents, without affecting normal hematopoietic stem cells. The Phase 1 trial is a two-part, open-label, dose-escalation study to determine the maximum tolerated dose and dose limiting toxicities of tegavivint, as a monotherapy and in combination with decitabine, in patients with relapsed and refractory AML. "Having recently established the

drug's safety and clinical activity in a proof-of-concept Phase 1 study in desmoid tumors, we are expanding our clinical footprint to address additional cancers characterized by beta-catenin overexpression such as AML, NSCLC, and certain pediatric cancers," said Rahul Aras, Ph.D., CEO of Iterion Therapeutics. The company received a $15.9 million CPRIT Product Development Research grant (CP130058) in 2019.

6. Perimeter Medical Imaging AI, Inc. announced on November 2, 2021, approval of its Investigational Device Exemption ("IDE") application by the U.S. Food and Drug Administration to conduct a multi-center study to evaluate the FDA breakthrough-device-designated Perimeter B-Series OCT (Optical Coherence Tomography) imaging system that uses ImgAssist AI technology to identify regions of interest and assess the impact on re-operation rates for patients undergoing breast conservation surgery. The goal of this study is to compare the use of Perimeter B-Series imaging technology with artificial intelligence against the standard of care and determine if it can improve surgeon's ability to reduce re-operation rates. "Importantly, Perimeter's novel imaging technology with AI fits into the routine surgical process with no additional imposition to the patient as it examines a tissue sample that is already being extracted," commented principal investigator Alastair Thompson, M.D., Section Chief of Breast Surgery at Baylor College of Medicine and the Co-Associate Director for Clinical Research at Dan L. Duncan Comprehensive Cancer Center. More than 300 patients across eight U.S. clinical sites will participate in the pivotal study. Perimeter Medical Imaging AI received a $7.4 million CPRIT Company Relocation and Product Development Research grant (DP190087) in 2019.

7. Iterion Therapeutics, Inc. announced the initiation of a Phase 1 clinical trial to investigate tegavivint in a first-line combination study with osimertinib in previously untreated patients with metastatic epidermal growth factor receptor (EGFR)-positive Non-Small Cell Lung Cancer (NSCLC) on December 9, 2021. Tegavivint is a potent and selective first-in-class small molecule inhibitor of Transducin beta-like Protein One (TBL1). NSCLC is the most common type of lung cancer, accounting for 85% of all lung cancer diagnoses, according to the American Society of Clinical Oncology. This trial has the potential to help this enormous patient population and to further demonstrate tegavivint's unique mechanism of action of TBL1 inhibition, thereby disrupting the oncogenic activity of beta-catenin. Tegavivint has already demonstrated safety in desmoid tumor patients and is currently under investigation in additional clinical trials as a potential treatment for acute myeloid leukemia and solid and hematologic pediatric tumors," said Rahul Aras, Ph.D., CEO of Iterion. Iterion received a $16 million CPRIT Product Development grant (CP130058) in 2014.

8. OncoNano Medicine, Inc. announced the appointment of Brett Giroir, M.D., to the company's Board of Directors on December 17, 2021. Dr. Giroir is a physician-scientist and innovator who has dedicated his career to improving public health and medicine. He previously served as the 16th Assistant Secretary for Health in the U.S. Department of Health and Human Services, Acting FDA Commissioner and Admiral in the U.S. Public Health Service Commissioned Corps. Dr. Giroir also served as the U.S. Representative to the Executive Board of the World Health Organization within the Department of State, and was on the front lines of the COVID-19 response as a member of the White House Task Force and the national lead for testing and diagnostics. Dr. Giroir is a graduate of Harvard University and The University of Texas Health Science Center, where he served on the faculty for ten years. OncoNano Medicine, Inc. has received three CPRIT Product Development Research grants (DP140072, DP190066, DP200081) in 2014, 2019 and 2020, respectively, for a total of $31.4 million.

9. Perimeter Medical Imaging AI, Inc., announced the expansion of its ongoing pivotal study to include an additional clinical trial site at Baylor College of Medicine on January 11, 2022, under the direction of principal investigator Alastair Thompson, M.D., professor, Section Chief of Breast Surgery, and Olga Keith Wiess Chair of Surgery at Baylor College of Medicine and Co-Associate Director for clinical research at the Dan L. Duncan Comprehensive Cancer Center. A multi-center, randomized, two-arm clinical trial is underway to measure the

effectiveness of the Perimeter B-Series OCT imaging platform combined with ImgAssist artificial intelligence (AI) technology in reducing the number of unaddressed positive margins in breast lumpectomy procedures when used in addition to standard intraoperative margin assessment. Perimeter Medical Imaging, Inc. received a $7.4 million CPRIT Company Relocation and Product Development grant (DP190087) in 2019.

10. Salarius Pharmaceuticals, Inc. announced a definitive agreement with DeuteRx, LLC to acquire an oral, small molecule targeted protein degradation portfolio on January 13, 2022. The acquisition includes a lead drug candidate that Salarius has renamed SP-3164 (formerly DRX-164), the related patent family, including issued composition of matter patents, and the opportunity to develop additional undisclosed cancer-fighting assets in the targeted protein degradation space. Targeted protein degradation takes advantage of the body's own degradation system to promote the selective elimination of disease-causing proteins. "This strategic acquisition is a transformative event for Salarius that significantly expands our development pipeline while building upon the momentum of our lead clinical-stage candidate, seclidemstat, our existing infrastructure and our scientific expertise," said David Arthur, CEO of Salarius Pharmaceuticals. Salarius Pharmaceuticals received a $16.1 million CPRIT New Company Product Development Award (DP160014) in 2016.

11. ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced the first patient dosed in the Company-sponsored Phase 1/2 study to evaluate the safety, tolerability and preliminary efficacy of ESSA's lead product candidate, EPI-7386, in combination with Astellas Pharma Inc.'s and Pfizer Inc.'s ligand-binding domain androgen receptor inhibitor, enzalutamide, in patients with metastatic castration-resistant prostate cancer ("mCRPC") on January 19, 2022. The goal of the phase 1 was to evaluate the safety and tolerability of the drug combination and establish the recommended phase 2 doses for EPI-7386 and enzalutamide when dosed in combination. The phase 2 study will enroll 120 mCRPC patients who have not received second-generation antiandrogen therapies. The goal of the phase 2 part of the study is to evaluate the safety, tolerability and antitumor activity of EPI-7386 in combination with a fixed dose of enzalutamide compared with enzalutamide as a single agent. In 2014, ESSA Pharma Inc. received a $12 million CPRIT Product Development Research grant (CP130020).

12. On February 3, 2022, Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, named Daniela Santiesteban, Ph.D., as Director of the company's new targeted protein degradation program. In this newly created position, Dr. Santiesteban will lead the Salarius team working with DeuteRx to complete studies that the company will include in its Investigational New Drug (IND) applications for SP-3164 and other targeted protein degradation assets emerging from the purchased intellectual property portfolio. Her appointment immediately follows Salarius' recent strategic expansion into the targeted protein degradation field through its acquisition of SP-3164 from DeuteRx LLC. Salarius expects to file an IND for SP-3164 with the FDA in the first half of 2023. Dr. Santiesteban joined Salarius in 2018 and has served in several key roles including leading business development activities, pursuing academic and business partnerships, and supporting the company's product development strategy. Salarius Pharmaceuticals received a $16.1 million CPRIT New Company Product Development Award grant (DP160014) in May 2016.

13. On February 9, 2022, Texas Medical Center Innovation (TMCi) announced the next 20 participants for its nine-month cancer therapeutics accelerator. TMCi established the Accelerator for Cancer Therapeutics (ACT) in 2019 using grant funding from CPRIT. The ACT provides resources at no cost for business development, education and networking to selected researchers and early-stage biotech companies to advance their platforms toward commercialization. The 20 participants for the accelerator's second nine-month cohort include six startup companies and 18 academic research faculty at institutions from across the state of Texas.

Ten of the researchers are CPRIT grantees, including two CPRIT scholars. The ACT program accepted its inaugural class of 15 researchers and startups in 2021. During the initial 2021 nine-month program, participants created three new startups. Participants also submitted multiple Small Business Innovation Research and Small Business Technology Transfer grant proposals. Submitting grant proposals is a goal for each of the companies going through the program. The Texas Medical Center Foundation received a $5.4 million CPRIT Core Facility Support Awards grant (RP190674) in 2019.

14. Salarius Pharmaceuticals Inc., a Houston-based clinical-stage biopharmaceutical company, reported important corporate events and its financial results for the full year and the fourth quarter ended December 31, 2021. As stated by David Arthur, CEO of Salarius Pharmaceuticals, "2022 is a year of significant optimism at Salarius given the potential value-building opportunities and milestones on the horizon. Salarius is moving to rapidly advance the development of SP-3164 with plans to file an IND and initiate our first clinical trial for that program in 2023. Building on our optimism around SP-3164 and based on the abundance of preclinical and clinical data collected around its predecessor, avadomide, it is our belief that SP-3164 will establish a superior safety profile with the potential to be more effective. Additionally, we continue advancing the clinical exploration of seclidemstat, our oral, reversible LSD1 inhibitor and Salarius' most advanced investigational cancer drug candidate. We look forward to providing data updates in the coming months." Salarius Pharmaceuticals received a $16 million CPRIT Product Development Research grant (DP160014) in 2016.

15. Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), announced the appointment of Gabriela Gruia, M.D., to its Board of Directors on March 2, 2022. Dr. Gruia is an oncologist with over 25 years of experience in oncology drug development, spanning cell and gene therapy, bi-specifics, biologics, immunotherapy, and small molecules. Dr. Gruia previously served as Chief Development Officer at Ichnos Sciences as well as Senior Vice President and Global Head of Regulatory Affairs for Novartis Oncology. Molecular Templates, Inc. received two CPRIT Product Development Research grants (CC121020, DP160071) in 2011 and 2016, for a total of $25.8 million.

16. Invectys, Inc. announced on March 9, 2022, that Wayne A. Marasco, M.D., Ph.D., joined its Scientific Advisory Board. Dr. Marasco is professor of medicine at Harvard Medical School, Lab Chief in the Department of Cancer Immunology & Virology at Dana-Farber Cancer Institute, and a Primary Faculty Member of Harvard Stem Cell Institute. He is also board certified in internal medicine and infectious diseases. Dr. Marasco brings to Invectys his pioneering expertise in the field of human antibody engineering and cellular/stem cell therapies. He is senior author for more than 175 peer reviewed publications, chapters, books and monographs and holds over 75 patents. Dr. Marasco is the Founding Scientific Director of the National Foundation for Cancer Research Center for Therapeutic Antibody Engineering, Humanized Mouse Center at Dana-Farber and at HSCI's Humanized Neonatal Mouse Center. US News & World Report named him among the 13 top scientists in their field as the 21st century medicine "Pioneers of Medicine Progress." Invectys, Inc. received a $14.19 million CPRIT Product Development Research, Company Relocation grant (DP200034) in May 2020.

17. Perimeter Medical Imaging AI announced the initiation of a multi-center, randomized, two-arm pivotal clinical trial to evaluate its Perimeter B-Series OCT with ImgAssist AI for use during breast conservation surgery on March 10, 2022. Jeremy Sobotta, Perimeter's Chief Executive Officer, said that the initiation of this pivotal trial marks another milestone in their ATLAS AI project and an important step in the clinical development of breakthrough-device-designated Perimeter B-Series OCT with AI assisted software, which represents the next generation of commercially available flagship Perimeter S-Series OCT. Clinical data generated from this study will provide supporting evidence that their technology can help breast cancer physicians improve

outcomes for patients and potentially reduce the burden of additional costs within the healthcare system. Perimeter Medical Imaging AI received a $7.4 million CPRIT Company Relocation and Product Development Research grant (DP190087) in 2019.

18. Dialectic Therapeutics Inc., a clinical stage biotechnology company based in Dallas, announced that the U.S. Food and Drug Administration has granted orphan drug designation to DT2216 for the treatment of T-cell lymphoma on March 14, 2022. The FDA subsequently granted fast track designation to DT2216 for adult patients with relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma on April 5, 2022. As the company's lead drug compound, DT2216 is the first generation of compound built using Dialectic's novel proprietary platform, Antiapoptotic Protein Targeted Degradation (APTaD). "The FDA's decision to grant orphan drug designation underscores our belief that DT2216 could be a promising therapeutic for T-cell lymphoma patients," said Dr. David Genecov, President and CEO of Dialectic. "There is a critical unmet need for people diagnosed with this rare cancer, in which current approved therapies have relatively low response rates." DT2216 is currently in a Phase 1 clinical trial designed as an open-label, first-in-human, dose escalation study in patients with histologically or cytologically confirmed advanced or metastatic solid tumors and hematologic malignancies who are no longer responsive to approved or accepted standard-of-care interventions. Patients in the Phase 1 trial will receive a single intravenous infusion of DT2216 twice weekly for at least four weeks, with each cycle consisting of 28 days. Dialectic received two CPRIT grants, a $3 million Seed Award for Product Development Research grant (DP200018) in 2020 and a $14.5 million Texas Company Product Development Awards grant (DP210005) in 2021.

19. On May 10, 2022, OncoNano Medicine, Inc. announced the appointment of Elina Lavit as Vice President, Business Development. Mrs. Lavit brings over 18 years of experience in leadership roles in organizations ranging from start-ups to Fortune 100 corporations in various therapeutic areas, including oncology and surgery. At OncoNano, Mrs. Lavit will be responsible for driving strategic partnerships and business development activities to support the company's continued growth. "OncoNano continues to build momentum as we are entering a rapid phase of growth with pegsitacianine poised to enter Phase 3 clinical trials and our first therapeutic candidate, ONM 501, currently in IND-enabling studies," said Martin Driscoll, CEO of OncoNano Medicine, Inc. Mrs. Lavit previously served as Executive Director, Program Management at Taysha Gene Therapies, and as Director of Program Management at Myokardia. University. OncoNano Medicine, Inc. has received three CPRIT Product Development Research grants (DP140072, DP190066, DP200081) in 2014, 2019 and 2020, respectively, for a total of $31.4 million.

20. Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Their lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Aravive hosted a Key Opinion Leader Symposium on the GAS6-AXL signaling pathway and the Company's lead drug candidate, batiraxcept on May 11, 2022. The FDA granted batiraxcept Fast Track Designation and Orphan Drug Designation by the European Commission for platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase 3 trial in platinum resistant ovarian cancer, a Phase 1b/2 trial in clear cell renal cell carcinoma, and a Phase 1b/2 trial in pancreatic adenocarcinoma. Houston-based Aravive received a $20 million CPRIT Product Development Research grant (DP150127) in 2016.

21. Immatics Inc. announced on May 10, 2022, the initiation of a Phase 1 clinical trial with its T cell engaging receptor (TCER) IMA401 for patients with recurrent and/or refractory solid tumors. IMA401 is the most advanced product candidate from Immatics' TCR Bispecific pipeline targeting an HLA-A*02-presented peptide

derived from both MAGEA4 and MAGEA8. Immatics will develop TCER IMA401 in collaboration with Bristol Myers Squibb. Immatics is responsible for conducting the Phase 1 clinical trial. The primary objectives of the clinical trial are to determine the maximum tolerated dose and/or the recommended phase 2 dose for IMA401 in biomarker-positive patients with recurrent and/or refractory solid tumors. Secondary objectives are to characterize safety and tolerability, evaluate initial anti-tumor activity and assess pharmacokinetics of IMA401. Researchers will conduct the trial at up to 15 centers in Germany, with the first site already initiated. Immatics US, Inc., received a $19.6 million CPRIT New Company Product Development Award grant (DP150029) in 2015.

22. Immatics Inc. announced on May 18, 2022, dosing of the first patient in the IMA203 and nivolumab combination Phase 1b dose expansion cohort. This cohort will evaluate Immatics' TCR-engineered cell therapy (TCR-T) approach ACTengine(TM) IMA203 targeting an HLA-A*02-presented peptide derived from PRAME, in combination with Bristol Myers Squibb's PD-1 checkpoint inhibitor nivolumab, in patients with advanced solid tumors. The combination treatment of IMA203 and nivolumab is part of Immatics' strategy to realize the full clinical potential of IMA203 TCR-T targeting PRAME. Based on this strategy, the company has expanded the IMA203 trial to a total of three Phase 1b dose expansion cohorts. The objectives of the study will be to evaluate the safety, biological activity, and initial anti-tumor activity of the IMA203 and nivolumab combination. Immatics US, Inc., received a $19.6 million CPRIT New Company Product Development Award grant (DP150029) in 2015.

23. On June 1, 2022, OncoNano Medicine, Inc. announced the appointment of Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer. Dr. Krishnan will be responsible for formulating and leading all clinical development efforts and operations at OncoNano. Additionally, Dr. Krishnan will develop and implement the strategic clinical plans for OncoNano, including the creation of a medical affairs team, as the company further advances its clinical oncology development programs. Dr. Krishnan previously served as Chief Medical Officer at Arcus Biosciences, where he led the expansion of the company's portfolio into novel indications and combinations, as well as the initiation of several pivotal Phase 3 trials. Prior to joining Arcus, he served as Executive Medical Director at Astex Pharmaceuticals, providing strategic direction and tactical support across multiple programs in all phases of development. Dr. Krishnan has also held positions in clinical drug development at Genentech, FivePrime Therapeutics, BioMarin and Amgen. OncoNano Medicine and Dr. Krishnan received two CPRIT Product Development Research grants (DP190066, DP200081) in 2019 and 2020 for a total of $25.4 million.

24. Perimeter Medical Imaging AI, Inc., announced on June 1, 2022, the appointment of Chris Scott as Chief Financial Officer, effective immediately. Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Chris joins us at time when we have a strong balance sheet and see exciting milestones ahead, including the continued commercial launch of our flagship S-Series OCT and the ongoing development of our next-gen AI technology now being evaluated in a pivotal trial." Mr. Scott brings to Perimeter his extensive experience in finance and accounting, as well as operations at a public company within the medtech sector. Prior to joining Perimeter, Mr. Scott served as Chief Financial and Operating Officer at iRadimed Corporation since December 2013. Perimeter Medical Imaging AI, Inc. received a $7.4 million CPRIT Product Development Research grant (DP190087) in August 2019.

25. On June 3, 2022, Aravive, Inc., announced the appointment of Rudy Howard as Chief Financial Officer. Prior to joining Aravive, Mr. Howard served as the Chief Financial Officer of vTv Therapeutics Inc., a clinical-stage pharmaceutical company. Prior to joining vTv Therapeutics Inc., he served as the Chief Financial Officer of SciQuest, Inc., an international spend-management software company. From November 2008 until joining SciQuest, Mr. Howard served as Senior Vice President and Chief Financial Officer of MDS Pharma Ser-

vices, a pharmaceutical services company. Aravive's lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, inhibiting metastasis, tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept received Fast Track Designation from the FDA and Orphan Drug Designation by European Commission in platinum resistant ovarian cancer. Aravive, Inc. received a $20 million CPRIT New Company Product Development Award grant (DP150127) in November 2015.

26. On June 7, 2022, Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc., a leading genome editing company, announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer. As part of the licensing agreement, Immatics gains non-exclusive rights to Editas Medicine's CRISPR technology and intellectual property. Editas Medicine is the exclusive licensee of Harvard and Broad Institute's Cas9 patent estates and Broad Institute's Cas12a patent estate for human medicines. By combining Editas Medicine's gene editing technology with Immatics' ACTallo® allogeneic, off-the-shelf adoptive cell therapy platform based on gamma-delta T cells, researchers can redirect gamma-delta T cells to cancer cell targets with the goal of creating cells with enhanced tumor recognition and destruction. Immatics, Inc. received a $19.65 million CPRIT New Company Product Development Award grant (DP150029) in February 2015.

27. Medicenna Therapeutics Corp. announced on June 9, 2022, that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,352,402 titled, "Interleukin-4 Receptor-Binding Fusion Proteins and Uses Thereof." The patent provides intellectual property protection for composition and methods of treating degenerative diseases via administration of a fusion protein comprising an IL-4 or IL-13 Superkine and an anti-apoptotic Bcl-2 family polypeptide. The patent's term extends into at least 2038 without accounting for any potential extensions. "This latest patent strengthens our IP protection, diversifies our pipeline while underscoring the versatility of the Superkine platform," said Fahar Merchant, Ph.D., President and CEO of Medicenna. Dr. Marchant added that by utilizing directed evolution, the Superkine platform creates highly selective tunable cytokines that researchers can seamlessly integrate with a variety of additional therapeutic moieties. This has allowed the researchers to generate novel biologics targeting a broad spectrum of conditions such as autoimmune disorders and neurodegenerative diseases. This IP portfolio and preclinical data allow Medicenna to facilitate the advancement of these discovery-stage assets and to generate value across several therapeutic areas while remaining primarily focused on oncology and their lead MDNA11 program. Medicenna Therapeutics received a $14.1 million CPRIT New Company Product Development Award grant (DP150031) in 2015.

28. Perimeter Medical Imaging AI, Inc. announced on June 22, 2022, the appointment of Anantha Kancherla to its Board of Directors following his nomination by Social Capital, effective immediately. Jeremy Sobotta, Perimeter's CEO stated, "[Antatha's] pioneering experience applying artificial intelligence and machine learning software solutions at industry leaders such as Microsoft, Facebook, and Lyft will be invaluable as we advance our next-gen AI technology. With our flagship S-Series technology commercially available across the U.S., and our B-Series with AI currently under evaluation in a pivotal clinical trial, this is an incredibly exciting time at Perimeter." Dr. Kancherla was most recently an engineering director at Meta, where he headed its AI platform. He previously served as vice president of Engineering at Lyft where he led the Level5 software team responsible for building the self-driving car. Dr. Kancherla also previously worked on Windows at Microsoft focusing on DirectX, Graphics, and UI. In his former role at Facebook, Dr. Kancherla participated in pioneering the building of mobile software at scale for more than 1 billion users worldwide. Perimeter Medical Imaging AI, Inc. received a $7.5 million CPRIT Product Development Research grant (DP190087) in August 2019.

29. On July 22, 2022, Medicenna Therapeutics Corp. announced new clinical data on safety, pharmacodynamics and anti-tumor activity from the Phase 1/2 ABILITY study of MDNA11, the Company's long-acting IL-2 super agonist. The data provides preliminary evidence of MDNA11's single agent anti-cancer activity in patients with advanced solid tumors who have been unresponsive to other treatments. "The ABILITY Study's latest data add to a body of clinical evidence we believe supports our view on MDNA11's potential as a best-in-class IL-2 agonist," said Dr. Fahar Merchant, President and CEO of Medicenna. "Data from the trial's initial and mid-stage dose escalation cohorts showed signs of tumor control in four of ten evaluable patients with hard-to-treat cancers such as sarcomas and pancreatic cancer that are also highly resistant to immunotherapies." Pharmacodynamic data are consistent with MDNA11's novel 'beta-only' mechanism of action and pre-clinical evidence of tumor localization. Treatment with MDNA11 leads to multi-fold increases in anti-cancer immune cells without stimulation of cells that cause immunosuppression and toxicity typically associated with native IL-2 and its 'alpha-binding' variants. Encouraged by these early, researchers move forward to the next step of the ABILITY Study based on the evolving data as they escalate from 60 µg/kg to the 90 µg/ dose. Medicenna Therapeutics received a $14.1 million CPRIT New Company Product Development Award grant (DP150031) in 2015.

30. On August 2, 2022, Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and VolitionRx Limited, a multinational epigenetics company, announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition's Nu.Q® technology to support further development of Salarius' clinical stage drug, seclidemstat. Seclidemstat, a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression, is currently in Phase 1/2 clinical studies for solid and hematologic cancers where LSD1 is implicated in disease progression. David Arthur, Chief Executive Officer of Salarius explained, "Biomarkers allow for a noninvasive method for determining target engagement and potential drug activity in patients. So, this exciting research collaboration with Volition Rx Limited provides another tool to aid in the development of seclidemstat in clinic." Nu.Q® is a simple, easy-to-use, cost-effective blood test to diagnose and monitor a range of life-altering diseases including cancer in humans and animals. Salarius Pharmaceuticals, Inc. received a $16 million CPRIT New Company Product Development Award grant (DP160014) in 2016.

31. Perimeter Medical Imaging AI, Inc., a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, along with Pavilion Surgery Center, an affiliate of St. Joseph Hospital, jointly announced on August 3, 2022, the first commercial placement of the Perimeter S-Series OCT system in the state of California at Pavilion Surgery Center in Orange, CA. Perimeter S-Series OCT received FDA 510(k) clearance in 2021 and is a medical imaging tool that uses Optical Coherence Tomography (OCT) to provide clinicians with cross-sectional, real-time margin visualization (1-2 mm below the surface) of an excised tissue specimen. Steve Sapot, Perimeter's Chief Commercial Officer, explained, "We remain laser-focused on bringing Perimeter's transformative ultra-high resolution medical imaging technology directly into the OR to assist the surgeon with real-time intraoperative margin visualization – with the aim of improving patient outcomes and reducing healthcare costs." Perimeter Medical Imaging, Inc. received a $7.4 million CPRIT Company Relocation and Product Development grant (DP190087) in 2019.

32. Salarius Pharmaceuticals, Inc. announced in August the addition of five prestigious institutions to the open-label Phase 1/2 trial with seclidemstat in Ewing's sarcoma and FET-rearranged sarcomas on August 4, 2022. The Seattle Cancer Care Alliance (SCCA) and Oregon Health & Sciences University in Portland are now supporting trial enrollment in addition to the Mayo Clinic locations in Rochester, Minnesota, and Jacksonville,

Florida. Seclidemstat is a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression currently in Phase 1/2 clinical studies for the treatment of solid and hematologic cancers where LSD1 is implicated in disease progression. There are 13 additional clinical trial site locations including The University of Texas MD Anderson Cancer Center and Oncology Consultants, both located in Houston. David Arthur, chief executive officer of Salarius said, "We expect to report interim data in the second half of this year and are hopeful that seclidemstat, either alone or in combination with standard chemotherapy, will have a positive impact on the lives of these patients." Salarius Pharmaceuticals, Inc. received a $16 million CPRIT New Company Product Development Award grant (DP160014) in 2016.

33. On August 23, 2022, Immatics, Inc. announced treatment of the first patient in its Phase 1b expansion cohort C (NCT03686124) evaluating IMA203CD8, the company's 2nd generation TCR-T monotherapy approach where a proprietary CD8aß co-receptor is added to PRAME-specific IMA203 T cells. The IMA203CD8 Phase 1b dose expansion cohort will enroll up to 24 patients with different types of solid tumors across several clinical trial sites in the U.S. and in Germany. The 2nd generation TCR-T IMA203CD8 aims to further enhance depth and durability of anti-tumor responses and clinical outcomes of TCR-T targeting PRAME in patients with solid cancers. PRAME is highly prevalent across several indications thereby supporting the program's potential to reach a broad patient population. "With the initiation of the IMA203CD8 cohort, we can now test to what extent the interplay of engineered CD8 and CD4 T cells enhances anti-tumor activity in the clinical setting," said Dr. Cedrik Britten, M.D., Chief Medical Officer at Immatics. Immatics US, Inc., received a $19.6 million CPRIT New Company Product Development Award grant (DP150029) in 2015.

34. PLUS Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced an update on August 29, 2022, following receipt of formal minutes from a Type C meeting with the FDA. The meeting focused on the Company's Current Good Manufacturing Practice (cGMP) clinical and commercial manufacturing process for its lead investigational targeted radiotherapeutic, BMEDA-chelated Rhenium-186 NanoLiposome (186RNL), for recurrent glioblastoma (GBM). The FDA indicated agreement with the Company's proposed application of cGMP guidance for radiotherapeutics, small molecule drug products and liposome drug products for PLUS Therapeutics' novel 186RNL in support of ongoing and future glioblastoma clinical trials, manufacturing scale up and commercialization. Alignment with the FDA includes support of the Company's proposed controls and release strategy for the new drug substance and new drug product. The Company expects that this FDA feedback will apply to 186RNL used in other clinical development programs, including leptomeningeal metastases and pediatric brain cancer. "The Company remains on-track, on-time and on-budget to have cGMP 186RNL available in the second half of 2022 for all ongoing and planned ReSPECT™ clinical trials," said Marc H. Hedrick M.D., president and CEO of PLUS Therapeutics. PLUS Therapeutics, Inc. received a $17.6 million CPRIT Texas Company Product Development Awards grant (DP220039) in 2022.